RenovoRx, Inc.
RNXT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.13 | 0.62 | -0.12 | -0.23 |
| FCF Yield | -30.00% | -21.76% | -20.71% | -6.86% |
| EV / EBITDA | -2.15 | -4.03 | -3.84 | -13.01 |
| Quality | ||||
| ROIC | -174.82% | -3,916.15% | -161.45% | -36.95% |
| Gross Margin | 100.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.04 | 1.00 | 0.89 | 0.94 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | -100.00% |
| Free Cash Flow Growth | 10.93% | -16.42% | -48.56% | -68.11% |
| Safety | ||||
| Net Debt / EBITDA | 0.63 | 0.10 | 0.44 | 2.77 |
| Interest Coverage | 0.00 | -105.52 | -174.56 | -6.80 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 365.00 | 0.00 | 0.00 | 0.00 |